Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II
Executive Summary
Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased